Form 4: Revolution Medicines' General Counsel, Jeff Cislini, Reports Acquisition of Shares and Stock Options

Jeff Cislini, General Counsel of Revolution Medicines, reports the acquisition of 22,000 shares of common stock and 77,000 stock options.

Summary

• On March 1, 2025, Jeff Cislini, General Counsel of Revolution Medicines, acquired 22,000 shares of common stock at $0.
• Following this transaction, Cislini directly owns 61,222 shares of common stock, including 58,204 restricted stock units.
• Cislini also acquired options to purchase 77,000 shares of common stock at an exercise price of $40.74 on March 1, 2025.
• The options vest monthly over four years from March 1, 2025, and expire on February 28, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing reflecting compensation and equity ownership. The acquisition of shares and options by an executive is generally viewed as a positive, but it's a routine occurrence.

Positives

• The acquisition of shares and stock options by a key executive could be seen as a positive sign of confidence in the company's future prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the stock options suggests a commitment from the executive for the next four years.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's stock.

Stakeholder Impact

• Shareholders may view the executive's increased stake in the company as a positive signal.
• Employees may see this as a sign of stability and confidence in the company's leadership.

Key Dates